For research use only. Not for therapeutic Use.
TP-024 (FTBMT) is a selective GPR52 agonist with an EC50 of 75 nM[1]. TP-024 has antipsychotic and procognitive properties[2].
TP-024 (FTBMT) (0.1-10 μM) increases intracellular cAMP levels in CHO cells expressing human, mouse, or rat GPR52, with pEC50s of 7.03, 6.85, and 6.87, respectively[2].
TP-024 (FTBMT) (30 mg/kg, 90 minutes) exhibits antipsychotic-like activity without causing catalepsy in mice[2].
TP-024 (3 or 10 mg/kg, 48 hours) improves recognition and spatial working memory in rats[2].
TP-024 (3, 10, 30 mg/kg, 2 hours) stimulates neuronal activity in brain regions related to cognition[2].
| Catalog Number | I019638 |
| CAS Number | 1358575-02-6 |
| Synonyms | 4-[3-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-5-methyl-1,2,4-triazol-1-yl]-2-methylbenzamide |
| Molecular Formula | C19H16F4N4O |
| Purity | ≥95% |
| InChI | InChI=1S/C19H16F4N4O/c1-10-5-15(3-4-16(10)18(24)28)27-11(2)25-17(26-27)8-12-6-13(19(21,22)23)9-14(20)7-12/h3-7,9H,8H2,1-2H3,(H2,24,28) |
| InChIKey | TYXSIXOYTBHZFA-UHFFFAOYSA-N |
| SMILES | CC1=C(C=CC(=C1)N2C(=NC(=N2)CC3=CC(=CC(=C3)F)C(F)(F)F)C)C(=O)N |
| Reference | [1]. Tokumaru K, et al. Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists. Bioorg Med Chem. 2017 Jun 15;25(12):3098-3115. [2]. Nishiyama K, et al. FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia. J Pharmacol Exp Ther. 2017 Nov;363(2):253-264. |
